Amylyx Pharmaceuticals

#7076

Rank

$454.62M

Marketcap

United States

Country

Leadership team

Mr. Joshua B. Cohen (Co-Founder, Co-CEO & Director)

Mr. Justin B. Klee (Co-Founder, Co-CEO & Director)

Mr. James M. Frates M.B.A. (Chief Financial Officer)

Products/ Services

Biotechnology, Medical, Neuroscience, Pharmaceutical

Number of Employees

100 - 500

Headquarters

Cambridge, Massachusetts, United States

Established

2014

Company Registration

SEC CIK number: 0001658551

Traded as

AMLX

Social Media

URL

https://amylyx.com

Overview

Location

Recognition and Award

References

Summary

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

History

Founded in 2014, Amylyx has grown rapidly and today has operations in the US, Canada and Europe. After successful completion of two Phase 2 clinical trials, Amylyx is currently planning two late-phase clinical trials to start in 2018.

Mission

Our mission is to provide new treatments that extend and improve the quality of life for patients with neurodegenerative diseases.

Vision

Our vision is to become the leader in the development of treatments that prevent, delay or reverse the progression of neurological disease.

Key Team

Ms. Margaret M. Olinger M.B.A (Global Head of Commercial & Chief Commercial Officer)

Mr. Tom Holmes (Chief Technical Operations Officer)

Ms. Shauna Horvath (Head of Global Marketing)

Ms. Gina M. Mazzariello (Chief Legal Officer & Gen. Counsel)

Ms. Debra L. Canner (Global Head of HR & CHRO)

Dr. Patrick D. Yeramian M.D., MBA, Ph.D. (Global Head of Clinical R&D and Chief Medical Officer)

Mr. Chris Aiello (Head of Canada & GM)

Recognition and Awards

Amylyx has received numerous awards and recognition for its groundbreaking achievements, including a Breakthrough Therapy Designation from the FDA, a Technology Innovation Award from the National Institutes of Health, and a Gold Edison Award for groundbreaking innovations in medical research.